KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Operating Expenses: 2009-2024

Historic Operating Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $2.4 billion.

  • Biomarin Pharmaceutical's Operating Expenses rose 30.23% to $822.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 3.15%. This contributed to the annual value of $2.4 billion for FY2024, which is 6.10% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Operating Expenses of $2.4 billion as of FY2024, which was up 6.10% from $2.2 billion recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Operating Expenses high stood at $2.4 billion for FY2024, and its period low was $1.9 billion during FY2020.
  • Its 3-year average for Operating Expenses is $2.2 billion, with a median of $2.2 billion in 2023.
  • Data for Biomarin Pharmaceutical's Operating Expenses shows a peak YoY grew of 15.42% (in 2023) over the last 5 years.
  • Biomarin Pharmaceutical's Operating Expenses (Yearly) stood at $1.9 billion in 2020, then increased by 1.30% to $1.9 billion in 2021, then grew by 0.33% to $1.9 billion in 2022, then increased by 15.42% to $2.2 billion in 2023, then grew by 6.10% to $2.4 billion in 2024.